NeOnc logo.png
NeOnc Technologies Completes $18.5 Million Financing, Advances Phase II Clinical Trials for Enhanced Method of Delivering Novel Therapeutics to the Brain Under FDA Fast-Track Status
June 26, 2024 16:39 ET | NeOnc Technologies Holdings, Inc.
New investment and debt conversion by new and existing investors sets company’s post-money valuation at approximately $220 million, up 214% from previous funding round.Financing supports further...
neonc-logo-vector.png
NeOnc Technologies Formalizes Exclusive Global IP Licensing Agreement with USC for Enhanced Method of Delivering Novel Pharma Therapeutics to the Brain
April 24, 2023 11:00 ET | NeOnc Technologies Holdings, Inc.
LOS ANGELES, April 24, 2023 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc., a clinical stage medical biotechnology company, has formally secured exclusive worldwide rights from the University...
neonc-logo-vector.png
NeOnc Technologies Engages Anova Enterprises to Pursue Pediatric Brain Tumor Indication and FDA Fast-Track Status for NEO100®
March 06, 2023 08:00 ET | NeOnc Technologies Holdings, Inc.
Anova Enterprises, a clinical research organization, to prepare FDA Fast Track and Rare Pediatric Designation application for NEO100® for Pediatric High-Grade Gliomas (pHGGS) brain tumors.AnovaOS™...
National Brain Tumor Society & St. Baldrick's Foundation Partner to Defeat Deadliest Pediatric Cancer
October 06, 2016 14:53 ET | National Brain Tumor Society
BOSTON, MA--(Marketwired - October 06, 2016) - National Brain Tumor Society (NBTS), the largest nonprofit organization in the United States dedicated to the global brain tumor community, announced...